(e.g., ibrutinib, acalabrutinib, zalubrutinib)
before cancer treatment begins
Cardio-oncological evaluation* AND home blood pressure monitoring
every 3 months for 1 year, then every 6 months during all ibrutinib therapy
Continue cardio-oncological follow-up* **
Holter-ECG monitoring in addition to cardio-oncological follow-up*
* A cardio-oncological evaluation will systematically include at least one visit with blood pressure, blood glucose, lipid profile, GFR calculation, ECG and trans-thoracic echocardiography (TTE). Measurements of global longitudinal strain and 3D LVEF (if feasible) are recommended with the same machine.
** Holter-ECG monitoring can be considered even in asymptomatic patients to asymptomatic atrial fibrillation or ventricular arrhythmia.